Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 19, Issue 19, p.3918-28 (2001)


Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Drug Resistance, Neoplasm, Female, Humans, Iodine Radioisotopes, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Male, Middle Aged


To evaluate the efficacy and safety of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in patients with chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL) and to compare its efficacy to the patients' last qualifying chemotherapy (LQC) regimens.